drugset / Trial / NCT00197119

Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years

NCT00197119

Phase 3 Completed 244 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

To evaluate the persistence of anti-hepatitis A virus (anti-HAV) and anti-hepatitis B surface antigen (anti-HBs) antibodies up to 6, 7, 8, 9 and 10 years after administration of the first dose of the study vaccine.

Timeline

Start
2004-05
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator TWINRIX™ ADULT Vaccine 20 unknown Intramuscular
Comparator TWINRIX™ ADULT Vaccine 720 unknown Intramuscular
Comparator Twinrix™ Junior Vaccine 10 unknown Intramuscular
Comparator Twinrix™ Junior Vaccine 360 unknown Intramuscular